Inicio>>Signaling Pathways>> Neuroscience>> AChE>>Demecarium Bromide (BC-48)

Demecarium Bromide (BC-48)

Catalog No.GC31190

El bromuro de demecarium (BC-48) (BC-48) es un potente inhibidor de la colinesterasa, con una afinidad aparente (Kiapp) de 0,15 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Demecarium Bromide (BC-48) Chemical Structure

Cas No.: 56-94-0

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
87,00 $
Disponible
5mg
56,00 $
Disponible
10mg
82,00 $
Disponible
25mg
110,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Demecarium Bromide (BC-48) is a potent cholinesterase antagonist, with an apparent affinity (Kiapp) of 0.15 μM[1]. Demecarium Bromide (BC-48) is used as a glaucoma agent[2].

Demecarium Bromide (0.125 and 0.5%) causes long-term miosis and decreases intraocular pressure (IOP) in beagles with both normotensive eyes and inherited glaucoma[1].

[1]. Brown JH, et al. Activation and blockade of cardiac muscarinic receptors by endogenous acetylcholine and cholinesterase inhibitors. J Pharmacol Exp Ther. 1982 Oct;223(1):20-4. [2]. Gum GG, et al. Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93.

Reseñas

Review for Demecarium Bromide (BC-48)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Demecarium Bromide (BC-48)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.